5-Year Survival Among Patients With Advanced Melanoma, RCC, or NSCLC Treated With Nivolumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
JAMA Oncol 2019 Jul 25;[EPub Ahead of Print], SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, DF McDermott, JD Powderly, JA Sosman, MB Atkins, PD Leming, DR Spigel, SJ Antonia, A Drilon, JD Wolchok, RD Carvajal, MB McHenry, F Hosein, CT Harbison, JF Grosso, M SznolFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.